Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to delineate early neurological features and their progression in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in order to facilitate early diagnosis, prevent erroneous diagnosis and mistreatment and improve physician education about this relatively common yet under-recognized dementing disorder.

Patients with CADASIL suffer from a variant from migraine that differs from wild type migraine in terms of its severity, progressive nature and underlying pathophysiology. Recurrent stereotypic acute confusional state associated with the headache episodes in patients with CADASIL is a distinctive phenomenon, which if recognized will lead to an earlier and accurate diagnosis of this condition.

Specific Aims:

- Characterize the nature, frequency and severity of migraine in patients with CADASIL.

- Delineate the phenomenon of acute confusional migraine as a distinct subgroup of migraine and establish its prevalence in patients with CADASIL.

- Determine the latency between the onset of neurological symptoms including migraine, and diagnosis of CADASIL and the prevalence of misdiagnosis.


Clinical Trial Description

New York University School of Medicine, Division of Neurogenetics is conducting a new research study for patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). We are inviting anyone age 18 or older with a confirmed diagnosis of CADASIL to participate. We greatly appreciate your help in this regard. Please be assured that if you participate, all the information you, your relatives or your physicians provide will be held in strict confidence.

CADASIL is often misdiagnosed due to lack of awareness of this condition among health care providers and because the disease can closely mimic other neurological conditions. People with CADASIL struggle to find a doctor who has knowledge about this condition. The purpose of this study is to better understand the early symptoms of CADASIL so doctors may learn to diagnose it early.

This research study will be based on review of medical information provided by you or your health care giver. If you are interested, please contact us by telephone. We will mail a questionnaire for you to fill out and return to us, and request a copy of your brain MRI, test results and office notes from your doctor. We will contact some people for a more detailed telephone interview. Your responses and questionnaire are still valuable even if we do not get other records. The estimated time to complete the questionnaire is about two hours. The telephone interview (if applicable) is expected to last for 30 to 45 minutes. It may be helpful to involve a family member or a friend while completing the questionnaire.

If you wish to participate in this study, please call our research office.We will tell you about the project and then, if you wish to participate, will mail you the questionnaires with return envelopes. Your participation and support is deeply appreciated. ;


Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01114815
Study type Observational
Source New York University School of Medicine
Contact
Status Completed
Phase N/A
Start date March 2009
Completion date March 2012

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Recruiting NCT05755997 - CERebrolysin In CADASIL Phase 2
Recruiting NCT06148051 - AusCADASIL: An Australian Cohort of CADASIL
Recruiting NCT04310098 - CADASIL Registry Study
Recruiting NCT05677880 - Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
Recruiting NCT02795052 - Neurologic Stem Cell Treatment Study N/A
Completed NCT02837354 - The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage? N/A
Recruiting NCT01361763 - Safety Study of Dabigatran in CADASIL Phase 2
Completed NCT02071784 - Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Completed NCT06072118 - Adrenomedullin for CADASIL Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT05473637 - Taiwan Associated Genetic and Nongenetic Small Vessel Disease
Enrolling by invitation NCT02032225 - Generation of a Cellular Model of CADASIL From Skin Fibroblasts N/A
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Active, not recruiting NCT04658823 - Efficacy and Safety of Tocotrienols in CADASIL Phase 2
Withdrawn NCT04334408 - Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Phase 2
Recruiting NCT05734378 - Prognosis of Cerebral Small Vessel Disease
Recruiting NCT05491980 - Florida Cerebrovascular Disease Biorepository and Genomics Center
Recruiting NCT04036084 - Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy
Completed NCT01865604 - Impact of tDCS on Cerebral Autoregulation N/A